摘要
目的探讨脾多肽注射液联合化疗治疗对激素受体阴性的中晚期子宫内膜癌的临床疗效。方法方便选取并回顾性分析该院2014年5月—2017年5月收治的60例中晚期激素受体阴性的子宫内膜癌患者,将其中脾多肽注射液联合TC方案化疗30例作为观察组,将单纯TC方案化疗30例作为对照组,比较两组患者疗效及不良反应情况,对患者免疫功能指标进行检测。结果研究组Ⅱ度以上骨髓抑制发生率40.0%,神经毒性发生率23.3%,均低于对照组(χ^2=4.290、4.590,P﹤0.05);两组患者恶心呕吐、肝损、脱发的发生率比较,差异无统计学意义(χ^2=0.000、0.140、0.000,P﹥0.05)。免疫指标方面:两组总T淋巴细胞均有下降,治疗组下降幅度较小(t=2.880,P﹤0.05)。Th细胞在对照组下降显著,而在治疗组无明显变化,Tc值治疗前后差异无统计学意义(t=1.84,P>0.05),Th/Tc的比值在治疗组变化不明显,而在对照组下降明显(t=3.400,P<0.05)。NK细胞比例对照组下降更明显(t=3.530,P<0.05)。结论具有双向免疫调节作用的脾多肽注射液联合化疗在中晚期子宫内膜癌治疗过程中可以减少Ⅱ度以上骨髓抑制、神经毒性发生率,并有一定的免疫保护作用,有效提高了中晚期子宫内膜癌患者免疫功能,使用过程安全,与既往学者研究结论基本一致,值得临床推广。
Objective To explore the clinical efficacy of spleen peptide injection combined with chemotherapy in the treatment of hormone receptor negative intermediate and advanced endometrial cancer.Methods convenient selection and retrospectively analyze 60 cases of hormone receptor negative uterus treated in our hospital from May 2014 to May 2017.For patients with endometrial cancer,30 cases of spleen polypeptide injection combined with TC regimen chemotherapy were used as the observation group,and 30 cases of pure TC regimen chemotherapy were used as the control group.The efficacy and adverse reactions of the two groups were compared,and the patient's immune function indicators were tested.Results The incidence of bone marrow suppression above 2 degrees in the study group was 40.0%,and the incidence of neurotoxicity was 23.3%,which were lower than those in the control group(χ^2=4.290,4.590,P<0.05).There was no significant difference in the incidence rate(χ^2=0.000,0.140,0.000,P>0.05).In terms of immune indicators:Total T lymphocytes decreased in both groups,and the decrease was smaller in the treatment group(t=2.880,P<0.05).Th cells decreased significantly in the control group,but there was no significant change in the treatment group.There was no statistically significant difference in Tc value before and after treatment(t=1.840,P>0.05).The ratio of Th/Tc did not change significantly in the treatment group,but in the control group.There was a significant decrease in the group(t=3.400,P<0.05).The proportion of NK cells decreased more significantly in the control group(t=3.530,P<0.05).Conclusion The spleen peptide injection with two-way immunomodulatory effect combined with chemotherapy can reduce the incidence of bone marrow suppression and neurotoxicity aboveⅡdegree during the treatment of end-stage endometrial cancer,and has a certain immune protection effect,which effectively improves the uterus in the middle-late stage.The immune function of endometrial cancer patients is safe to use,which is basically consisten
作者
鲍学浩
BAO Xue-hao(Department of Oncology,Dongfang Cancer Hospital,Huainan,Anhui Province,231200 China)
出处
《中外医疗》
2020年第15期107-109,共3页
China & Foreign Medical Treatment
关键词
脾多肽注射液联合化疗
子宫内膜癌
不良反应
细胞免疫功能
探讨
Spleen peptide injection combined with chemotherapy
Endometrial cancer
Adverse reactions
Cellular immune function
